Last updated: April 26, 2026
What is BARACLUDE and what supply claims exist?
BARACLUDE is the brand name for entecavir, an oral antiviral indicated for chronic hepatitis B. Across markets, BARACLUDE is manufactured and distributed through company-controlled and third-party channels that vary by region, with most formal “supplier” visibility coming from regulatory filings (NDA/labeling) and authorized product distribution structures rather than public supplier-of-every-ingredient disclosures.
Who supplies BARACLUDE (product manufacturers and labeling-linked entities)?
Public, regulator-facing supplier visibility typically identifies the marketing authorization holder and/or manufacturer(s) listed in the drug product labeling (for each region). For BARACLUDE, the key structured entities that appear in official labeling frameworks are:
| Role in supply chain |
Entity type |
What the public record usually shows for BARACLUDE |
| Marketing/authorization holder |
Labeling-linked company |
The firm responsible for placing the product on the market in a given jurisdiction |
| Drug product manufacturer |
Labeled manufacturer |
One or more manufacturing sites used for finished drug product (DP) |
| Distributor |
Labeled distributor or marketing entity |
Distribution is handled by the label holder and/or appointed distributors per region |
| Raw material API supplier |
Typically not publicly itemized |
API sourcing is generally not broken down in consumer-facing labels; it is more often handled through internal quality systems and confidential supply agreements |
API and drug substance supplier visibility
Drug substance (entecavir API) suppliers are not consistently disclosed in public BARACLUDE labeling. For branded antivirals like BARACLUDE, API supply typically comes from:
- The brand holder’s internal procurement, and/or
- Contract manufacturing organizations (CMOs) under quality agreements,
with supplier names and site details usually appearing in:
- Confidential sections of regulatory submissions, or
- Site master files and inspections, which are not typically extractable from public labels.
What suppliers matter for business decisions on BARACLUDE?
For R&D, procurement, or investment diligence around BARACLUDE, supplier analysis usually focuses on three concrete supplier categories:
-
Finished dose manufacturer(s) (DP)
- Determines stability, batch consistency, and cost.
- Often listed in jurisdiction-specific labeling.
-
API manufacturer(s) (drug substance)
- Determines impurity profile, regulatory history, and any supply risk.
- Rarely named in standard public labeling.
-
Excipients and fill-finish partners
- Determines tablet hardness, dissolution behavior, and packaging interoperability.
- Often tied to the DP manufacturing site and not named publicly.
How to interpret “supplier” in the BARACLUDE context
When a buyer or analyst says “suppliers for BARACLUDE,” it usually means one of the following, each with different levels of public disclosure:
| “Supplier” meaning |
Publicly disclosed in labeling? |
Practical procurement relevance |
| Finished product manufacturer |
Often yes |
High (delivery, batch-to-batch performance) |
| Distributor/marketing entity |
Often yes |
Medium (logistics, rebate contracts) |
| API supplier |
Commonly no |
High (regulatory and supply risk) |
| Excipients |
Usually no |
Medium (formulation risk, change control impact) |
What official records typically identify for BARACLUDE
For BARACLUDE, the most defensible public anchors for supply-chain entities are:
- Drug product labeling in each country
- Regulatory product dossiers (where accessible)
- FDA/EMA public review artifacts (limited)
These sources generally do not create a full “bill of materials supplier map” in public view for BARACLUDE.
Key takeaways
- BARACLUDE supply-chain “supplier” disclosure in the public domain is strongest for finished drug product manufacturer(s) and marketing/distribution entities shown in jurisdiction-specific labeling.
- API supplier identities for entecavir are usually not named in public BARACLUDE consumer-facing labeling, with most API sourcing detail handled inside confidential regulatory and quality documentation.
- For operational diligence, focus supplier verification on (1) DP manufacturing sites listed in labeling and (2) documented API control strategy within the regulatory dossier rather than relying on public labeling to name every upstream supplier.
FAQs
1) Are entecavir API suppliers listed on BARACLUDE packaging or label?
Typically no. Public labels generally list the drug name and composition at a high level but do not enumerate upstream API manufacturing sources.
2) Who are the “suppliers” most relevant to quality and supply continuity for BARACLUDE?
The finished dose (DP) manufacturer(s) and any distributor/marketing entities authorized for sale in the jurisdiction.
3) Do BARACLUDE suppliers differ by country?
Yes. Finished dose manufacturing, labeling, and distribution can vary by market due to regulatory approvals and contract manufacturing arrangements.
4) How can BARACLUDE manufacturing partners be verified for procurement?
By matching the labeled manufacturer and site details in the relevant jurisdiction’s official product labeling and regulatory listing.
5) Why are upstream API and excipient suppliers hard to see publicly for branded drugs like BARACLUDE?
Because supplier identities for API and excipients are usually managed through confidential supply agreements and detailed regulatory dossier sections rather than public labels.
References
- FDA. BARACLUDE (entecavir) drug label (access via Drugs@FDA).
- EMA. BARACLUDE (entecavir) product information (where applicable by jurisdiction).
